- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
- Interventions
- AdGMCAIX-transduced autologous dendritic cells, therapeutic autologous dendritic cells, laboratory biomarker analysis
- Biological · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 18,391
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Adult Solid Tumor
- Interventions
- CANscript
- Diagnostic Test
- Lead sponsor
- Mitra RxDx, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Timeline
- 2017 – 2019
- U.S. locations
- 30
- States / cities
- Gilbert, Arizona • Aurora, Colorado • Norwich, Connecticut + 23 more
- Conditions
- Dysmenorrhea, Heavy Menstrual Bleeding, Contraception
- Interventions
- Transabdominal Ultrasound
- Diagnostic Test
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 12 Years to 22 Years · Female only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Interventions
- celecoxib, therapeutic conventional surgery, pharmacological study, laboratory biomarker analysis
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Cancer
- Interventions
- AC regimen, cyclophosphamide, doxorubicin hydrochloride, paclitaxel
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3,871 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2014
- U.S. locations
- 526
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 359 more
- Conditions
- ER+ Breast Cancer, Breast Cancer, Aromatase Inhibitors
- Interventions
- White Wine, Grape Juice
- Other
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 21 Years to 90 Years · Female only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Metastatic Cancer, Metastatic Melanoma, Renal Cancer
- Interventions
- Anti-VEGFR2 CAR CD8 plus PBL, Cyclophosphamide, Aldesleukin, Fludarabine
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
- Interventions
- CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules
- Drug · Other
- Lead sponsor
- OPKO IP Holdings II, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Bannockburn, Illinois
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma, Cervical Carcinosarcoma, Cervical Squamous Cell Carcinoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Fallopian Tube Adenocarcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Squamous Cell Carcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Malignant Female Reproductive System Neoplasm, Malignant Ovarian Clear Cell Tumor, Malignant Ovarian Endometrioid Tumor, Malignant Ovarian Epithelial Tumor, Malignant Ovarian Mucinous Tumor, Malignant Peritoneal Neoplasm, Malignant Solid Neoplasm, Ovarian Carcinosarcoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Unresectable Melanoma, Uterine Corpus Carcinosarcoma
- Interventions
- Bevacizumab, Laboratory Biomarker Analysis, Nab-paclitaxel, Pharmacological Study
- Biological · Other · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more
- Conditions
- Menorrhagia
- Interventions
- NovaSure Endometrial Ablation
- Device
- Lead sponsor
- Hologic, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 318 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 14
- States / cities
- Chandler, Arizona • Arvada, Colorado • Sarasota, Florida + 11 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- OTL38, Intraoperative fluorescence imaging system
- Drug · Device
- Lead sponsor
- Chandru Sundaram
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana
- Conditions
- Overactive Bladder (OAB)
- Interventions
- FemPulse System
- Device
- Lead sponsor
- FemPulse Corporation
- Industry
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Fort Lauderdale, Florida
- Conditions
- Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Psychological Impact of Cancer, Recurrent Ovarian Carcinoma
- Interventions
- Communication Intervention, Educational Intervention, Internet-Based Intervention, Psychosocial Assessment and Care, Quality-of-Life Assessment, Questionnaire Administration
- Other · Procedure
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 485 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 144
- States / cities
- Phoenix, Arizona • Los Angeles, California • Mountain View, California + 94 more
- Conditions
- Metastatic Renal Cell Carcinoma, Renal Cell Carcinoma With Sarcomatoid Features
- Interventions
- Doxorubicin, Gemcitabine, G-CSF (granulocyte-colony stimulating factor), Neulasta
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 92
- States / cities
- Los Angeles, California • Aurora, Colorado • Aurora, Illinois + 56 more
- Conditions
- Fever
- Interventions
- Not listed
- Lead sponsor
- MemorialCare
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2009
- U.S. locations
- 2
- States / cities
- Long Beach, California • Orange, California
- Conditions
- Kidney Cancer
- Interventions
- aldesleukin, bevacizumab
- Biological
- Lead sponsor
- Jorge A. Garcia, MD
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- ADHD, Attention Deficit Hyperactivity Disorder
- Interventions
- Other
- Behavioral
- Lead sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- Other
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 312 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- HPV
- Interventions
- brief informational intervention to promote HPV vaccine acceptance
- Behavioral
- Lead sponsor
- Syracuse University
- Other
- Eligibility
- 11 Years and older
- Enrollment
- 614 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Syracuse, New York
- Conditions
- Mycoplasma Genitalium Infection
- Interventions
- Comparison of two standard of care regimens
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 99 Years · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Pregnancy Related, Pregnancy Complications, Pregnancy, High Risk
- Interventions
- Relugolix + Estradiol + Norethindrone Acetate
- Drug
- Lead sponsor
- Sumitomo Pharma Switzerland GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Marlborough, Massachusetts
- Conditions
- Overactive Bladder
- Interventions
- Medtronic Implantable Tibial Neuromodulation (TNM) System
- Device
- Lead sponsor
- MedtronicNeuro
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 7
- States / cities
- Marietta, Georgia • Englewood, New Jersey • Hamlet, North Carolina + 4 more
- Conditions
- Chronic Kidney Disease
- Interventions
- Kibow Biotics
- Dietary Supplement
- Lead sponsor
- Kibow Pharma
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Breast Cancer
- Interventions
- letrozole
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older · Female only
- Enrollment
- 261 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 48
- States / cities
- Huntsville, Alabama • Little Rock, Arkansas • Grass Valley, California + 43 more
- Conditions
- Complex Atypical Hyperplasia, Endometrial Cancer
- Interventions
- Metformin
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Cincinnati, Ohio